NASDAQ:KNSA - Kiniksa Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 109.61 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$11.45
▼ -0.02 (-0.17%)

This chart shows the closing price for KNSA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kiniksa Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KNSA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KNSA

Analyst Price Target is $24.00
▲ +109.61% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Kiniksa Pharmaceuticals in the last 3 months. The average price target is $24.00, with a high forecast of $24.00 and a low forecast of $24.00. The average price target represents a 109.61% upside from the last price of $11.45.

This chart shows the closing price for KNSA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Kiniksa Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2021WedbushLower Price TargetOutperform$32.00 ➝ $24.00High
11/24/2020Evercore ISIInitiated CoverageOutperformHigh
6/30/2020The Goldman Sachs GroupBoost Price TargetBuy$20.00 ➝ $33.00Medium
6/29/2020Bank of AmericaBoost Price TargetBuy$25.00 ➝ $40.00High
6/29/2020WedbushBoost Price Target$30.00 ➝ $38.00High
4/1/2020Bank of AmericaInitiated CoverageBuy$25.00High
3/11/2020JPMorgan Chase & Co.Boost Price TargetOverweight$22.00 ➝ $24.00High
12/6/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$16.00 ➝ $18.00High
8/14/2019WedbushReiterated RatingBuyHigh
8/14/2019JMP SecuritiesLower Price TargetMarket Outperform$35.00High
3/11/2019BarclaysInitiated CoverageOverweight ➝ Overweight$26.00Medium
12/12/2018WedbushReiterated RatingOutperform ➝ Outperform$31.00 ➝ $33.00Low
9/17/2018JMP SecuritiesBoost Price TargetOutperform$33.00 ➝ $44.00High
9/11/2018WedbushReiterated RatingOutperform$31.00High
6/18/2018JMP SecuritiesInitiated CoverageOutperform$33.00High
6/18/2018WedbushInitiated CoverageOutperform$31.00High
6/18/2018JPMorgan Chase & Co.Initiated CoverageOverweight$29.00High
6/18/2018The Goldman Sachs GroupInitiated CoverageNeutralHigh
(Data available from 10/18/2016 forward)

News Sentiment Rating

-0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Kiniksa Pharmaceuticals logo
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
Read More

Today's Range

Now: $11.45
Low: $11.44
High: $11.77

50 Day Range

MA: $12.04
Low: $10.78
High: $13.11

52 Week Range

Now: $11.45
Low: $10.65
High: $24.70

Volume

8,675 shs

Average Volume

449,875 shs

Market Capitalization

$784.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Kiniksa Pharmaceuticals?

The following equities research analysts have issued stock ratings on Kiniksa Pharmaceuticals in the last twelve months: Evercore ISI, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for KNSA.

What is the current price target for Kiniksa Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Kiniksa Pharmaceuticals in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 109.6%. Wedbush has the highest price target set, predicting KNSA will reach $24.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $24.00 for Kiniksa Pharmaceuticals in the next year.
View the latest price targets for KNSA.

What is the current consensus analyst rating for Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KNSA will outperform the market and that investors should add to their positions of Kiniksa Pharmaceuticals.
View the latest ratings for KNSA.

How do I contact Kiniksa Pharmaceuticals' investor relations team?

Kiniksa Pharmaceuticals' physical mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company's listed phone number is 448081896257 and its investor relations email address is [email protected] The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.